![A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer | Nature Communications A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer | Nature Communications](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-022-31704-7/MediaObjects/41467_2022_31704_Fig1_HTML.png)
A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer | Nature Communications
![Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study | BMC Cancer Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study | BMC Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12885-021-08275-9/MediaObjects/12885_2021_8275_Fig1_HTML.png)
Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study | BMC Cancer
![Cancers | Free Full-Text | Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study Cancers | Free Full-Text | Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study](https://www.mdpi.com/cancers/cancers-13-02797/article_deploy/html/images/cancers-13-02797-g001.png)
Cancers | Free Full-Text | Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study
![Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer - ScienceDirect Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2059702920326375-gr1.jpg)
Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer - ScienceDirect
![Protocol of the IntenSify‐Trial: An open‐label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab‐paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate Protocol of the IntenSify‐Trial: An open‐label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab‐paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate](https://ascpt.onlinelibrary.wiley.com/cms/asset/ca474d8a-3b8b-4de4-8388-e0d7e5ca1f1d/cts13661-fig-0002-m.jpg)
Protocol of the IntenSify‐Trial: An open‐label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab‐paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate
![Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation - International Journal of ... Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation - International Journal of ...](https://www.redjournal.org/cms/asset/40fc8a4b-a1dc-4631-a5db-4f6275e37cbf/gr1.jpg)
Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation - International Journal of ...
![Protocol of the IntenSify‐Trial: An open‐label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab‐paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate Protocol of the IntenSify‐Trial: An open‐label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab‐paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate](https://ascpt.onlinelibrary.wiley.com/cms/asset/9d6f693d-3199-46a1-99fc-9e9270054598/cts13661-fig-0001-m.jpg)
Protocol of the IntenSify‐Trial: An open‐label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab‐paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate
![A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact - ScienceDirect A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0959804921011655-ga1.jpg)
A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact - ScienceDirect
![Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab- paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer | Journal of Pancreatology Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab- paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer | Journal of Pancreatology](https://mednexus.org/cms/10.1097/JP9.0000000000000038/asset/c28bb572-1302-4653-9250-7ce30dad7578/assets/graphic/2096-5664-03-01-005-f001.png)
Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab- paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer | Journal of Pancreatology
![Life | Free Full-Text | A Review on the Efficacy and Safety of Nab- Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer Life | Free Full-Text | A Review on the Efficacy and Safety of Nab- Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer](https://pub.mdpi-res.com/life/life-12-00327/article_deploy/html/images/life-12-00327-ag.png?1645693413)
Life | Free Full-Text | A Review on the Efficacy and Safety of Nab- Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer
![Use of nab-paclitaxel and gemcitabine in pancreatic cancer without granulocyte colony-stimulating factor: A multicenter real-world experience - Angela Chen, Vincent H Ha, Sunita Ghosh, Carole R Chambers, Michael B Sawyer, 2022 Use of nab-paclitaxel and gemcitabine in pancreatic cancer without granulocyte colony-stimulating factor: A multicenter real-world experience - Angela Chen, Vincent H Ha, Sunita Ghosh, Carole R Chambers, Michael B Sawyer, 2022](https://journals.sagepub.com/cms/10.1177/10781552211038677/asset/images/large/10.1177_10781552211038677-fig2.jpeg)
Use of nab-paclitaxel and gemcitabine in pancreatic cancer without granulocyte colony-stimulating factor: A multicenter real-world experience - Angela Chen, Vincent H Ha, Sunita Ghosh, Carole R Chambers, Michael B Sawyer, 2022
![Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial - ScienceDirect Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0959804921001064-gr1.jpg)
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial - ScienceDirect
![Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRASG12D mutated pancreatic cancer in vivo model | Cell Death Discovery Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRASG12D mutated pancreatic cancer in vivo model | Cell Death Discovery](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41420-023-01397-y/MediaObjects/41420_2023_1397_Fig1_HTML.png)
Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRASG12D mutated pancreatic cancer in vivo model | Cell Death Discovery
![Use of nab-paclitaxel and gemcitabine in pancreatic cancer without granulocyte colony-stimulating factor: A multicenter real-world experience - Angela Chen, Vincent H Ha, Sunita Ghosh, Carole R Chambers, Michael B Sawyer, 2022 Use of nab-paclitaxel and gemcitabine in pancreatic cancer without granulocyte colony-stimulating factor: A multicenter real-world experience - Angela Chen, Vincent H Ha, Sunita Ghosh, Carole R Chambers, Michael B Sawyer, 2022](https://journals.sagepub.com/cms/10.1177/10781552211038677/asset/images/large/10.1177_10781552211038677-fig1.jpeg)
Use of nab-paclitaxel and gemcitabine in pancreatic cancer without granulocyte colony-stimulating factor: A multicenter real-world experience - Angela Chen, Vincent H Ha, Sunita Ghosh, Carole R Chambers, Michael B Sawyer, 2022
![Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial ... Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial ...](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13063-015-1101-7/MediaObjects/13063_2015_1101_Fig1_HTML.gif)